[
  {
    "ts": "2026-01-27T12:14:00+00:00",
    "headline": "Gene Therapy Investment Trends Strategic Intelligence Report 2026: Market to Reach $42.26 Billion by 2033 | Astute Analytica",
    "summary": "The global gene therapy market is experiencing rapid expansion, driven by advancements in CRISPR and viral vectors. The market focuses on treating genetic disorders, cancer, and rare diseases, with North America leading in adoption. Key players include Novartis, Gilead, and Sarepta.Chicago, Jan. 27, 2026 (GLOBE NEWSWIRE) -- According to recent data from Astute Analytica, the global gene therapy market was valued at US$ 9.42 billion in 2024 and is projected to hit the market valuation of US$ 42.2",
    "url": "https://finance.yahoo.com/news/gene-therapy-investment-trends-strategic-121400413.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "77de9d55-d31a-3958-9f77-8d5144f2648b",
      "content": {
        "id": "77de9d55-d31a-3958-9f77-8d5144f2648b",
        "contentType": "STORY",
        "title": "Gene Therapy Investment Trends Strategic Intelligence Report 2026: Market to Reach $42.26 Billion by 2033 | Astute Analytica",
        "description": "",
        "summary": "The global gene therapy market is experiencing rapid expansion, driven by advancements in CRISPR and viral vectors. The market focuses on treating genetic disorders, cancer, and rare diseases, with North America leading in adoption. Key players include Novartis, Gilead, and Sarepta.Chicago, Jan. 27, 2026 (GLOBE NEWSWIRE) -- According to recent data from Astute Analytica, the global gene therapy market was valued at US$ 9.42 billion in 2024 and is projected to hit the market valuation of US$ 42.2",
        "pubDate": "2026-01-27T12:14:00Z",
        "displayTime": "2026-01-27T12:14:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471",
          "originalWidth": 300,
          "originalHeight": 300,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JHwPm5XOBkH6S4g8iMmLiw--~B/aD0zMDA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 300,
              "height": 300,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SbelUm4u7tLxgdG5STxR1A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c69505cf1983c21fb029b9444d820471.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gene-therapy-investment-trends-strategic-121400413.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gene-therapy-investment-trends-strategic-121400413.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "SRPT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]